ClinicalTrials.gg
Not yet recruitingNCT07852663Updated Oct 8, 2026

PQLB vs TFPB in HALDN

An interventional study of Quadratus Lumborum Block type 2 and Transversalis Fascia Plane Block in Analgesia, Donor Nephrectomy and Postoperative Pain, sponsored by Koc University Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Koc University Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,107 studies in Pain, Postoperative with a site in Turkey — 266 open to participants now, 300 under way, none of them phase 3. Pain, Postoperative · Turkey.

Planned enrollment
716th of 892
54 · median 70
Started
2026
with 227 others
No phase
823 of 1,107
220 open now
Primary completion
2027-04
later than 237 of 299 live
Registered
1,058th of 1,107
by date

Among the 1,107 studies in Pain, Postoperative with a site in Turkey, this one is the 716th largest by planned enrollment of the 892 interventional ones that give a count, is one of 228 that started in 2026, is one of 823 with no phase, reaches primary completion later than 237 of the 299 other live ones, and was the 1,058th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

266 of the 1,107 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

261 more — sign in →

All 266 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,107 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

This prospective randomized non-inferiority trial is designed to compare postoperative analgesic effect of transversalis fascia plane block and posterior quadratus lumborum block in hand assisted laparoscopic donor nephrectomy. Posoperative opioid consumption, numeric rating scale pain scores and adverse effects will be assessed during the trial.

Read the detailed description

Hand-assisted laparoscopic donor nephrectomy (HALDN) is a widely used technique for kidney donor surgeries. Management of postoperative pain is important to provide patient comfort. Main components of postoperative pain is from incision sides. Regional anesthesia techniques may reduce postoperative opioid requirements in this patient group, but the optimal block for this procedure has not been established.

A competed but not yet published study in our clinic found that transversalis fascia plane block significantly reduced analgesic requirements after HALDN. Its a deep block, that involves injection below transversalis fascia and above perirenal fat tissue. Its location can be seen relatively close to the important structures of such as peritoneum and retroperitenoum. Posterior quadratus lumborum block (PQLB, also known as quadratus lumborum block -2 or QLB-2) is considered effective in renal surgery for other indications and PQLB may provide analgesia comparable to TFPB for HALDN surgery. Possible benefit of PQLB over TFPB is superficial anatomical location of PQLB and its relative distance to areas such as retroperitoneum and peritoneum. Results in our center shows TFPB effective in HALDN procedure, therefore it is selected as the control group intervention This trial is designed to determine whether PQLB is not inferior to TFPB for cumulative opioid consumption during the first 24 postoperative hours for HALDN surgery. Opioid consumption, pain scores and adverse effects through first 48 hours postoperatively and patient satisfaction at 48th hour will be evaluated as a secondary outcome to describe the duration of postoperative analgesic effect.

Routine preanesthetic premedication with midazolam 0.03 mg/kg will be administered to both study groups. Anesthesia will be induced with fentanyl 1-2 micrograms/kg IV, propofol 1-2 mg/kg IV, and rocuronium 0.9-1.2 mg/kg IV.

General anesthesia will be maintained with 40% inspired oxygen, desflurane at approximately 1 minimum alveolar concentration, and a remifentanil infusion at 0 - 0.02 micrograms/kg/min. The actual doses of all intraoperative opioids will be recorded. Intraoperative fentanyl and remifentanil administered before the end of surgery will not be included in the primary outcome.

The assigned block will be performed after induction of general anesthesia and before surgical incision, with the participant in the lateral position and the operative side facing upward.

Standard anesthesia monitoring will continue throughout block placement and until the surgery ends.

At the end of surgery, all participants will receive paracetamol 1 g IV and morphine 0.05 mg/kg IV in addition to regional anesthesia technique as standardized multimodal analgesia regiment. The end-of-surgery morphine dose will be included in cumulative postoperative opioid consumption.

Participants will be extubated in the operation room when clinically appropriate and transferred to the post-anesthesia care unit.

In the PACU, a morphine PCA device will be started using a 1 mg IV bolus, an 8-minute lockout interval, and no basal infusion. Device-generated records will be used to determine PCA consumption. In PACU, if NRS is greater than or equal to 4 is observed, fentanyl 50 micrograms IV will be administered up to three times at 15-minute intervals. All fentanyl administered in the PACU will be included in cumulative postoperative opioid consumption.

For 48 hours, all participants will receive paracetamol 1 g IV three times daily and morphine PCA using the same settings. In surgical ward, If NRS is greater than or equal to 4 is observed, tramadol 100 mg IV will be administered as rescue analgesia in accordance with institutional prescribing limits.

Every rescue dose and any additional analgesic treatment required for clinical care will be recorded. Tramadol will be converted to IV morphine equivalents and included in cumulative postoperative opioid consumption.

Morphine PCA cumulative consumption, rescue opioid and analgesic use, NRS at rest, NRS during cough, and opioid-related and block-related adverse events will be assessed at postoperative hours 1, 3, 6, 12, 24, and 48.

Patient satisfaction with postoperative pain management will be assessed at postoperative hour 48.

Protocol deviations, withdrawal, loss to follow-up, unblinding, and missing assessments will be recorded whenever they occur.

03

Conditions studied

  • Analgesia
  • Donor Nephrectomy
  • Postoperative Pain
  • Fascial Plane Block
  • Quadratus Lumborum Block
  • Transversalis Fascia Plane Block

Browse trials for

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Approved and scheduled for hand-assisted laparoscopic donor nephrectomy.
  • Aged 18-84 years.
  • Classified as I-II.
  • Able to provide written .
  • Written informed consent obtained before any study-specific procedure.

Exclusion criteria

Exclusion Criteria:

  • Allergy to any study medication.
  • Chronic use of opioids or opioid-receptor agonists.
  • History of psychiatric illness
  • Chronic organ failure.
  • Inability to communicate sufficiently for or outcome assessment.
  • Refusal of the study intervention or follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    PQLB

    Posterior quadratus lumborum block will be administered by the senior anesthesiologist, following the anesthesia induction and before the surgical incision.

    Procedure: Quadratus Lumborum Block type 2

  • Active comparator
    TFPB

    Transversalis fascia plane block will be administered by the senior anesthesiologist, following the anesthesia induction and before the surgical incision.

    Procedure: Transversalis Fascia Plane Block

Interventions

  • ProcedureQuadratus Lumborum Block type 2

    Posterior Quadratus Lumborum Block Technique A 2-6 MHz convex ultrasound probe will be positioned parallel to and over the iliac crest. Anterior and posterior scanning will identify the quadratus lumborum, psoas major, transversus abdominis, external and internal oblique muscles, lumbar vertebral body and transverse process, and perirenal adipose tissue. An 80-mm Stimuplex needle will be advanced in-plane under continuous ultrasound visualization. After negative aspiration, 30 mL of 0.25% bupivacaine will be injected into the posterior fascial plane of the quadratus lumborum muscle. Spread of the solution will be observed continuously using ultrasound, with repeated aspiration during injection.

    Also known as: QLB-2, PQLB, Posterior quadratus lumborum block

  • ProcedureTransversalis Fascia Plane Block

    Transversalis fascia plane block administration technique: A 2-6 MHz convex ultrasound probe will be positioned parallel to and over the iliac crest. Anterior and posterior scanning will identify the quadratus lumborum, psoas major, transversus abdominis, external and internal oblique muscles, lumbar vertebral body and transverse process, and perirenal adipose tissue. An 80-mm Stimuplex needle will be advanced in-plane under continuous ultrasound visualization. After negative aspiration, 30 mL of 0.25% bupivacaine will be injected over the perirenal adipose tissue beneath the transversus abdominis fascia. Spread of the solution will be observed continuously using ultrasound, with repeated aspiration during injection to reduce the risk of intravascular administration.

    Also known as: TFPB

06

What researchers measure

Primary outcomes

  1. Postoperative opioid consumption for 24 hours

    The primary outcome is cumulative opioid consumption from the end of surgery through postoperative hour 24, expressed as IV morphine equivalents. Postoperative opioids will be converted to IV morphine equivalents using the ENCORE Study conversion table. The following conversion factors will be used: IV fentanyl: dose in micrograms × 0.066 = IV morphine equivalents in mg. IV tramadol: dose in mg × 0.1 = IV morphine equivalents in mg.

    Time frame: postoperative 24 hours

Secondary outcomes

  1. postoperative opioid consumption for 48 hours

    Cumulative opioid consumption from the end of surgery through postoperative hour 48, expressed as IV morphine equivalents. Assesment will be made at postoperative 1,3,6,12,24 and 48th hour. Postoperative opioids will be converted to IV morphine equivalents using the ENCORE Study conversion table. The following conversion factors will be used: IV fentanyl: dose in micrograms × 0.066 = IV morphine equivalents in mg. IV tramadol: dose in mg × 0.1 = IV morphine equivalents in mg.

    Time frame: postoperative 48 hours

  2. pain score

    Pain will be assesed by NRS scores at rest and cough, expressed drom 0 to 10. Assesment will be made at postoperative 1,3,6,12,24 and 48th hour.

    Time frame: postoperative 48 hours

  3. adverse effects

    Incidence and details of nausea, vomiting, pruritus, allergic reaction, sedation, respiratory depression, urinary retention, LAST, bleeding or hematoma, infection, persistent sensory or motor deficit, nerve injury, visceral or renal injury, and any other opioid or block-related adverse event through 48 hours.

    Time frame: postoperative 48 hours

  4. patient satisfaction

    6\. Patient satisfaction at 48 hours, assessed by asking: "How satisfied were you with your postoperative pain management?" The response will range from 0 to 10.

    Time frame: postoperative 48 hours

07

Study locations

1 site
08

References and documents

Publications

  • Ozkalayci O, Karakaya MA, Yenigun Y, Cetin S, Darcin K, Akyollu B, Arpali E, Kocak B, Gurkan Y. Effects of erector spinae plane block on opioid consumption in patients undergoing hand-assisted laparoscopic donor nephrectomy: a randomized controlled trial. Minerva Anestesiol. 2024 Mar;90(3):154-161. doi: 10.23736/S0375-9393.23.17706-6. Epub 2024 Feb 2. PubMed 38305014 ↗
  • Dupuis M, Bacci A, Adolle A, Sourd D, Vilotitch A, Bouzat P. Regional Analgesia Through Posterior Quadratus Lumborum Block in Laparoscopic and Robot-Assisted Nephrectomies: A Retrospective Observational Study. Anesth Analg. 2026 Feb 1;142(2):425-428. doi: 10.1213/ANE.0000000000007702. Epub 2025 Aug 29. No abstract available. PubMed 40880271 ↗
  • De Cassai A, Dost B, Tulgar S, Ciftci B, Diwan S, Gurkan Y. Regional Anaesthesia Techniques in Liver and Kidney Transplantation: A Narrative Review in Donors and Recipients. Turk J Anaesthesiol Reanim. 2026 Aug 28;54(4):236-247. doi: 10.4274/TJAR.2026.262509. PubMed 42664388 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 2 updates
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and responsible party
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852663
Lead sponsor
Koc University Hospital
Collaborators
Koç University School of Medicine
Responsible party
Eren Yavuz AÇIKALIN (Principal investigator, Koç University) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Eren Y AÇIKALIN, MD
Contact
erenyacikalin@gmail.com
+90 533 747 21 48

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion